Verona Pharma plc

NasdaqGM:VRNA

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

💊 Pharmaceuticals

Location

United Kingdom

Market Cap

USD 8.02 B

Share Price

USD 94.32

Avg Daily Volume

1,526,222

Change (1 day)

3.74%

Change (1 year)

542.07%

Change (YTD)

103.10%

Verona Pharma plc Share Price Year-To-Date (YTD) return on June 20, 2025: 103.10%

Verona Pharma plc Share Price Year-To-Date (YTD) return is 103.10% on June 20, 2025. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance. Year-to-Date (YTD) return is is the percentage change in the price of a stock from the start of the calendar year up to the current date, it shows how much the stock has gained or lost since the beginning of the year.

Verona Pharma plc 52-week low Share Price is USD 94.32 on June 20, 2025, which is 0.00% below the current Share Price.
Verona Pharma plc 52-week low Share Price is USD 14.46 on June 20, 2025, which is -84.67% below the current Share Price.
Verona Pharma plc average Share Price for the last 52 weeks is USD 46.83.

Daily

From:

To:

Zoom:

Key data

Date	Share Price Year-To-Date (YTD) return	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)	Price to Sales Ratio (P/S)

NasdaqGM: VRNA

Verona Pharma plc

CEO	Dr. David S. Zaccardelli Pharm.D.
IPO Date	April 28, 2017
Location	United Kingdom
Headquarters	3 More London Riverside
Employees	209
Sector	🏥 Health Care
Industries Clinical Trials 💊 Pharmaceuticals

Description

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.